Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile

A formulation, comprising:

• a suspension of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) or a salt, co-crystal, or polymorph thereof, in an amount of about 0.5% w/v to about 3.5% w/v,
• a non-ionic surfactant selected from the group consisting of a polysorbate surfactant, a block copolymer of ethylene oxide, propylene oxide surfactant, poloxamer, tyloxapol, and combinations thereof;
• a suspending agent selected from the group consisting of carbomer, hydroxypropyl methyl cellulose (hypromellose), polyethylene glycol, and combinations thereof;
• a tonicity agent selected from the group selected from mannitol, glycerin, xylitol, sorbitol and propylene glycol, and combinations thereof;
• a buffer;
• optionally, a salt;
• optionally, a preservative;
• and
• water in quantity sufficient (qs) to 100%.

A formulation, comprising:

• a suspension of polymorphic form B of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I), in an amount of about 0.5% w/v to about 2.5% w/v,
• tyloxapol in an amount of about 0.04 w/v to about 0.06% w/v;
• carbomer homopolymer Type B in an amount from about 0.05% w/v to about 0.4% w/v;
• glycerin in an amount of from about 0.5% w/v to about 5% w/v;
• a buffer selected from edetate, phosphate, borate, tromethamine, or combinations thereof;
• sodium chloride in an amount of from 0.01% w/v to about 1% w/v;
• and
• water qs to 100%;
• wherein the formulation has a pH in the range of from about 5.5 to about 8.0.